Venous thromboembolism after orthopedic surgery: Implications of the choice for prophylaxis

Thrombosis Research

Volumn 121, Issue 1, 2007, Pages 17-24

  Shorr, Andrew F ^a   Kwong, Louis M ^b   Sarnes, Matthew ^c   Happe, Laura ^c   Farrelly, Eileen ^c   Mody Patel, Nikita ^d  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c XCENDA   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Deep vein thrombosis; Orthopedic surgery; Outcomes; Prophylaxis; Pulmonary embolism

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HIP FRACTURE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; KNEE ARTHROPLASTY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM;

AGED; CHEMOPREVENTION; COHORT STUDIES; DALTEPARIN; DATA COLLECTION; ENOXAPARIN; FEMALE; HEPARIN; HUMANS; MALE; ORTHOPEDIC PROCEDURES; POLYSACCHARIDES; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM;

EID: 35648992543     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.02.013     Document Type: Article

References (27)

1. White R.H. The epidemiology of venous thromboembolism. Circulation 107 23 suppl 1 (2003) I4-I8
2. Heit J.A., Cohen A.T., Anderson Jr. F.A., and on Behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal venous thromboembolism (VTE) events in the US. Blood 106 (2005) 267a [abstract 910]
3. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 338S-400S
4. Nicolaides A.N., Breddin H.K., Fareed J., et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 20 (2001) 1-37
5. Anderson Jr. F.A., Wheeler H.B., Goldberg R.J., et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151 (1991) 933-938
6. Anderson F.A., and Spencer F.A. Risk factors for venous thromboembolism. Circulation 107 (2003) I9-I16
7. Haake D.A., and Berkman S.A. Venous thromboembolic disease after hip surgery. Risk factors, prophylaxis, and diagnosis. Clin Orthop Relat Res 242 (1989) 212-231
8. McGart G.M., and Kayser S.R. Therapeutic equivalency of low-molecular-weight heparin. Pharmacotherapy 36 (2002) 1042-1057
9. Eriksson B.I., Kalebo P., Anthymyr B.A., et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Jt Surg Am Vol 73 (1991) 484-493
10. Buller H.R., Davidson B.L., Decousus H., et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 (2003) 1695-1702
11. Turpie A.G., Eriksson B.I., Lassen M.R., et al. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopedic surgery. J South Orthop Assoc 11 (2002) 182-188
12. Turpie A.G., Bauer K.A., Eriksson B.I., et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359 (2002) 1721-1726
13. Lindenauer P.K., Pekow P., Wang K., et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 353 (2005) 349-361
14. Ouriel K., Kaul A.F., and Leonard M.C. Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis. J Vasc Surg 40 (2004) 971-977
15. Orrick J.J., Segal R., Johns T.E., et al. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to infectious diseases society of America guidelines. PharmacoEconomics 22 (2004) 751-757
16. Blanchette C.M., Wang P.F., Joshi A.V., et al. Cost and utilization of blood transfusion associated with spinal surgeries in the United States. Eur Spine J 15 (2006) 1-11
17. Geerts W.H., Heit J.A., Clagett G.P., et al. Prevention of venous thromboembolism. Chest 119 (2001) 132S-175S
18. Charlson M.E., Pompei P., Ales K.L., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
19. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992) 613-619
20. Bernardini J., Callen S., Fried L., et al. Inter-rater reliability and annual rescoring of the Charlson comorbidity index. Adv Perit Dial 20 (2004) 125-127
21. Roos L.L., Sharp S.M., and Cohen M.M. Comparing clinical information with claims data: some similarities and differences. J Clin Epidemiol 44 (1991) 881-888
22. Roos L.L., Sharp S.M., Cohen M.M., et al. Risk adjustment in claims-based research: the search for efficient approaches. J Clin Epidemiol 42 (1989) 1193-1206
23. O'Connor G.T., Plume S.K., Olmstead E.M., et al. A regional prospective study of in-hospital mortality associated with coronary artery bypass grafting. The Northern New England Cardiovascular Disease Study Group. JAMA 266 (1991) 803-809
24. Eriksson B.I., Bauer K.A., Lassen M.R., et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345 (2001) 1298-1304
25. Bauer K.A., Eriksson B.I., Lassen M.R., et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345 (2001) 1305-1310
26. Lassen M.R., Bauer K.A., Eriksson B.I., et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359 (2002) 1715-1720
27. Bullano M.F., Willey V., Hauch O., et al. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 11 (2005) 663-673